Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Department of Pharmacology and Experimental Therapeutics (2)
- Thomas Jefferson University (2)
- A Phase I Study of Ad5-GUCY2C-PADRE in Stage I and II Colon Cancer Patients (1)
- ACS (1)
- Adult; African American; Article; Asian; body mass; capillary density; cardiovascular risk; controlled study; disease association; endothelial dysfunction; female; forearm blood flow; human; insulin resistance; insulin sensitivity; major clinical study; male; microangiopathy; multiple linear regression analysis; obesity; priority journal; Quantitative Insulin Sensitivity Check Index; young adult (1)
-
- Department of Family and Community Medicine (1)
- Division of Biostatistics (1)
- Gene Transcription (1)
- Geriatric (1)
- Humans (1)
- Immunologic Factors (1)
- Immunotherapy (1)
- Medication errors (1)
- Medications (1)
- Multiple Sclerosis (1)
- Oncology (1)
- Pharmacists (1)
- Plasminogen Activator Inhibitor Type 1 (1)
- Polypharmacy (1)
- Pregnane X Receptor (1)
- Senior Adult Oncology Center (1)
- Sidney Kimmel Medical College (1)
- Thomas Jefferson University; Statins (1)
- Publication
-
- Department of Medical Genetics Faculty Papers (1)
- Department of Neurology Faculty Papers (1)
- Department of Pharmacology and Experimental Therapeutics Faculty Papers (1)
- Department of Pharmacology and Experimental Therapeutics Posters (1)
- Population Health Matters (Formerly Health Policy Newsletter) (1)
- Publication Type
Articles 1 - 5 of 5
Full-Text Articles in Medicine and Health Sciences
Pharmacists On The Front Lines Of Polypharmacy: The Individualized Medication Assessment And Planning (Imap) Project To Improve Medication Use In Senior Adults With Cancer, Ginah Nightingale Pharmd, Bcop, Laura T. Pizzi Pharmd, Mph, Emily Hajjar Pharmd, Bcps, Bcacp, Cgp, Elizabeth Pigott, Margaret Wang, Shannon Doherty, Kristine Swartz Md, Andrew Chapman Do, Facp
Pharmacists On The Front Lines Of Polypharmacy: The Individualized Medication Assessment And Planning (Imap) Project To Improve Medication Use In Senior Adults With Cancer, Ginah Nightingale Pharmd, Bcop, Laura T. Pizzi Pharmd, Mph, Emily Hajjar Pharmd, Bcps, Bcacp, Cgp, Elizabeth Pigott, Margaret Wang, Shannon Doherty, Kristine Swartz Md, Andrew Chapman Do, Facp
Population Health Matters (Formerly Health Policy Newsletter)
No abstract provided.
Emerging Immunopharmacological Targets In Multiple Sclerosis., Mojtaba Farjam, Guang-Xian Zhang, Bogoljub Ciric, Abdolmohamad Rostami
Emerging Immunopharmacological Targets In Multiple Sclerosis., Mojtaba Farjam, Guang-Xian Zhang, Bogoljub Ciric, Abdolmohamad Rostami
Department of Neurology Faculty Papers
Inflammatory demyelination of the central nervous system (CNS) is the hallmark of multiple sclerosis (MS), a chronic debilitating disease that affects more than 2.5 million individuals worldwide. It has been widely accepted, although not proven, that the major pathogenic mechanism of MS involves myelin-reactive T cell activation in the periphery and migration into the CNS, which subsequently triggers an inflammatory cascade that leads to demyelination and axonal damage. Virtually all MS medications now in use target the immune system and prevent tissue damage by modulating neuroinflammatory processes. Although current therapies such as commonly prescribed disease-modifying medications decrease the relapse rate …
A Phase I Study Of Ad5-Gucy2c-Padre In Stage I And Ii Colon Cancer Patients, Adam E. Snook, Trevor R. Baybutt, Michael J. Mastrangelo, Nancy L. Lewis, Scott D. Goldstein, Walter K. Kraft, Yaa D. Oppong, Terry Hyslop, Ronald E. Myers, Vitali Alexeev, Laurence C. Eisenlohr, Takami Sato, Scott A. Waldman
A Phase I Study Of Ad5-Gucy2c-Padre In Stage I And Ii Colon Cancer Patients, Adam E. Snook, Trevor R. Baybutt, Michael J. Mastrangelo, Nancy L. Lewis, Scott D. Goldstein, Walter K. Kraft, Yaa D. Oppong, Terry Hyslop, Ronald E. Myers, Vitali Alexeev, Laurence C. Eisenlohr, Takami Sato, Scott A. Waldman
Department of Pharmacology and Experimental Therapeutics Posters
Background
Ad5-GUCY2C-PADRE is a replication-deficient human type 5 recombinant adenovirus (Ad5) vaccine encoding guanylyl cyclase C (GUCY2C) fused to the PAn DR Epitope (PADRE). GUCY2C, a paracrine hormone receptor producing the second messenger cyclic GMP (cGMP), is selectively expressed by intestinal epithelial cells and a subset of hypothalamic neurons, but not other tissues. Importantly, GUCY2C is over-expressed in nearly all primary and metastatic human colorectal tumors. Preclinical studies in mice demonstrated selective tolerance of GUCY2C-specific CD4+ T cells, but not CD8+ T or B cells, necessitating inclusion of the exogenous CD4+ T helper cell epitope PADRE to maximize GUCY2C-specific CD8+ …
Association Of Adipokines With Insulin Resistance, Microvascular Dysfunction, And Endothelial Dysfunction In Healthy Young Adults., Cindy Cheng, Md, Phd, Constantine Daskalakis
Association Of Adipokines With Insulin Resistance, Microvascular Dysfunction, And Endothelial Dysfunction In Healthy Young Adults., Cindy Cheng, Md, Phd, Constantine Daskalakis
Department of Pharmacology and Experimental Therapeutics Faculty Papers
Proinflammatory adipokines (inflammation markers) from visceral adipose tissue may initiate the development of insulin resistance (IR) and endothelial dysfunction (ED). This study's objective was to investigate the association of five inflammation markers (CRP and four adipokines: IL-6, TNFα, PAI-1, and adiponectin) with IR (quantitative insulin resistance check index (QUICKI)), microvascular measures (capillary density and albumin-to-creatinine ratio (ACR)), and endothelial measures (forearm blood flow (FBF) increases from resting baseline to maximal vasodilation). Analyses were conducted via multiple linear regression. The 295 study participants were between 18 and 45 years of age, without diabetes or hypertension. They included 24% African Americans and …
Statins Increase Plasminogen Activator Inhibitor Type 1 Gene Transcription Through A Pregnane X Receptor Regulated Element., Frederick M Stanley, Kathryn M Linder, Timothy J Cardozo
Statins Increase Plasminogen Activator Inhibitor Type 1 Gene Transcription Through A Pregnane X Receptor Regulated Element., Frederick M Stanley, Kathryn M Linder, Timothy J Cardozo
Department of Medical Genetics Faculty Papers
Plasminogen activator inhibitor type 1 (PAI-1) is a multifunctional protein that has important roles in inflammation and wound healing. Its aberrant regulation may contribute to many disease processes such as heart disease. The PAI-1 promoter is responsive to multiple inputs including cytokines, growth factors, steroids and oxidative stress. The statin drugs, atorvastatin, mevastatin and rosuvastatin, increased basal and stimulated expression of the PAI-1 promoter 3-fold. A statin-responsive, nuclear hormone response element was previously identified in the PAI-1 promoter, but it was incompletely characterized. We characterized this direct repeat (DR) of AGGTCA with a 3-nucleotide spacer at -269/-255 using deletion and …